INTRODUCTION
============

The ideal goal of antidepressant treatment for patients with major depressive disorder (MDD) is to achieve full recovery of individual, occupational, and psychosocial functions. However, lower remission/response rates and higher relapse rates have been consistently reported in real world treatment setting \[[@b1-cpn-17-495]--[@b3-cpn-17-495]\]. In addition, some sub-populations of MDD including mixed or anxious features are known to present poor clinical outcomes than those without such subsymptoms \[[@b4-cpn-17-495]\].

Likewise, the literature shows 'mixed feature' are present approximately in 30% of patients with MDD depending on methodological approach \[[@b5-cpn-17-495]--[@b7-cpn-17-495]\]. These symptoms can significantly increase risk for suicidal behaviour, result in poor antidepressant treatment response, substance abuse, relapse/recurrence, and (hypo)manic switch in patients with MDD \[[@b5-cpn-17-495]\]. Aripiprazole has been widely accepted and used for the treatment of MDD in clinical practice today; however, there has been no such information on the use of aripiprazole for the treatment of MDD with mixed specifier (MDDM) yet \[[@b8-cpn-17-495].[@b9-cpn-17-495]\].

The pharmacological characteristics and proven augmentation efficacy of aripiprazole for MDD warrant its use for the treatment of MDDM. Aripiprazole's partial agonist effects on D2/D3, 5-HT and 5-HT1A as well as its antagonist effects on 5-HT6, 5-HT7 and 5-HT2C receptors, leading to alteration of dopamine, serotonin and norepinephrine in specific brain areas have been considered in favour of improvement of mood symptoms \[[@b10-cpn-17-495]\]. In addition aripiprazole has shown substantial improvement of variation in mood, impulsivity, agitation, anxiety and irritability which are commonly seen in MDDM \[[@b11-cpn-17-495]\]. Aripiprazole has shown potential as proper augmentation agent for patients with MDD regardless of such sub-symptoms including other clinical factors according to recent researches \[[@b12-cpn-17-495]--[@b14-cpn-17-495]\]. In addition, there has been a putative hypothesis proposing some clinical similarities between MDDM, neuroleptic-induced dysphoria, withdrawal syndromes from dopaminergic drugs, and other behavioural syndromes arising from sudden dopamine depletion \[[@b15-cpn-17-495]\]. In this context, recent positron emission tomography (PET) study has revealed the main effects of aripiprazole would be produced by potentiation of dopaminergic activity \[[@b16-cpn-17-495]\]. In the study, 14 MDD patients, who had failed 8 weeks of antidepressant therapy with selective serotonin reuptake inhibitors, underwent 6-\[18F\]-L-DOPA (F-DOPA) PET scans before and after aripiprazole treatment; 11 responded to aripiprazole augmentation. Whole brain, voxel-wise comparisons of pre- and post-aripiprazole scans revealed increased F-DOPA trapping in the right medial caudate of aripiprazole augmentation responders \[[@b16-cpn-17-495]\]. An exploratory analysis of depressive symptoms revealed that such responders experienced large improvements only in putatively dopaminergic symptoms of lassitude and inability to feel \[[@b16-cpn-17-495]\].

Given above findings, we may assume that aripiprazole could be a potential agent as an augmentation therapy for treatment of MDDM patients. This retrospective study is thus proposed to observe how well aripiprazole works to treat MDDM in routine practice and provide a bridging data expanding to future double-blind randomized clinical trials (RCTs).

METHODS
=======

This study aimed to observe the potential utility of aripiprazole for treatment of MDDM (the Diagnostic and Statistical Manual of Mental Disorders 5th edition, DSM-5) \[[@b17-cpn-17-495]\] patients who have shown inadequate response to ongoing antidepressant treatment in routine clinical practice. The study was conducted in two university-based teaching hospitals. The MDDM diagnosis was confirmed when the patient met the full criteria of MDD episode and had simultaneously at least three of the following manic/hypomanic symptoms defined as DSM-5 (e.g., elevated and expansive mood, inflated self-esteem, talkativeness, flight of ideas, increased energy, increased or excessive involvement in activities that have a high potential for painful consequences, and decreased need for sleep) during the majority of days during the current or most recent episode of MDD.

All data collection was done for those who were treated with aripiprazole to treat symptoms of MDDM in routine outpatient practice for 8 weeks (week --8, baseline; week 0, endpoint). Aripiprazole was not intentionally used for study purpose; the treatment was completely based on clinical purpose and clinicians' proper judgment that the patients may have clinical benefits with the use of aripiprazole. Aripiprazole was added on current anti-depressant without dose restriction. The inclusion criteria are as follows: patients with MDDM, patients with inadequate antidepressant response (less than 50% improvement after at least 6-week antidepressant treatment), and patients with aripiprazole treatment to augment current antidepressant effect. Patients having other than MDD, other antipsychotics, mood stabilizers, psychostimulants, and change of antidepressant during observation period were excluded.

The primary efficacy was the mean change of Montgomery--Åsberg Depression Rating Scale (MADRS) \[[@b18-cpn-17-495]\] total scores from week --8 to week 0 and the secondary measures were mean changes in the Clinical Global Impression-Severity (CGI-S), Young Mania Rating Scale (YMRS) \[[@b19-cpn-17-495]\], Sheehan Disability scale (SDS) \[[@b20-cpn-17-495]\], and CGI-Clinical Benefit (CGI-CB) \[[@b21-cpn-17-495]\] total scores. Proportions of responder (≥50% reduction of MADRS total score at the end of treatment) and remitter (≤10 of MADRS total score at the end of treatment) were also collected as well as proportion of patients achieving improvement in CGI-CB score at the end of treatment to measure clinical benefit. CGI-CB score of 1 indicates the greatest benefit (effectiveness) with least burden (adverse events, AEs) from treatment, whereas score of 10 indicates the least benefit with the greatest burden from the treatment. The proportion of patients achieving 1 or 2 scores of CGI- Improvement at the end of treatment was also collected. Any occurrence of AEs throughout the study was reported.

The sample size of the present study was more than 95%, with observed mean difference in MADRS at the end of treatment (d = 7.1, standard deviation = 6.8), under an alpha value of 0.05 with two tailed. Analyses will include intent-to-treat for the end of treatment. Non-parametric analyses were done if the data distribution was not in normative range after Kolmogorov--Smirnov test, otherwise all data was analyzed by parametric analyses. Descriptive statistics, Wilcoxon signed rank test (or paired *t* test), chi-square test were performed where appropriate. Statistical significance was determined at *p* \< 0.05. Statistical analysis was performed using the NCSS ver. 07 for Windows (NCSS Inc., Kaysville, UT, USA) program.

The present study has been thoroughly reviewed and approved by local Institutional Review Board (approval number: HC16RIMI0112), and was conducted in compliance with the Declaration of Helsinki.

RESULTS
=======

Thirty-eight patients were enrolled and analyzed during the study. The sample included a greater proportion of male patients (65.8%) with approximately 28 years old. The mean duration of MDD was about 4 years. The baseline MADRS and YMRS total scores were approximately 22 and 9, respectively. The most common antidepressant and antianxiety medication were escitalopram and lorazepam, respectively. The mean aripiprazole dose was 4.0 (± 0.8) mg/day during the study. [Table 1](#t1-cpn-17-495){ref-type="table"} displays baseline clinical and demographical of patients in detail.

The changes of MADRS, CGI-S, YMRS, SDS, and CGI-CB total scores from baseline to the endpoint were 7.1, −0.8, −4.9, −4.1, and −3.6, respectively (all *p* \< 0.0001) ([Fig. 1](#f1-cpn-17-495){ref-type="fig"}). Each assessment score has decreased by 31.9%, 19.5%, 55.1%, 23.6%, and 45.0%, respectively from baseline to the endpoint.

At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively ([Fig. 2](#f2-cpn-17-495){ref-type="fig"}). The responder rates by CGI and YMRS score criteria were approximately 47% and 61%, respectively, at the endpoint ([Fig. 3](#f3-cpn-17-495){ref-type="fig"}).

In total, approximately 79% of patients (n = 30) showed a decrease in CGI-CB score at the endpoint. In detail, The most frequent score at baseline on the CGI-CB was 10 (n = 15), indicating unchanged/worse in therapeutic effect and outweigh therapeutic effect in burden of AEs, followed by scores of 7 (n = 9), 8 (n = 7), 4 (n = 5) and 3 (n = 1) / 9 (n = 1) indicating minimal to moderate therapeutic effect and none to significant interference in burden of AEs. At the endpoint, the most frequent scores at baseline on the CGI-CB were 4 (n = 10), 3 (n = 7), and 1 (n = 6) indicating moderate to marked therapeutic effect and none to no significant interference in burden of AEs, followed by scores of 7 (n = 7), 8 (n = 3), 2 (n = 2), 10 (n = 2), and 6 (n = 1) indicating unchanged/worse to marked therapeutic effect and none to outweigh therapeutic effect in burden of AEs. The CGI-CB improver rates scoring 1 to 4 (likely beneficial) or 5 to 10 (less likely beneficial) were 66% and 34%, respectively ([Fig. 4](#f4-cpn-17-495){ref-type="fig"}).

Increased appetite, somnolence, and headache were reported in only three patients during the study. There was no extrapyramidal symptoms (EPS) or movement-related AEs. The Barnes Akathisia Rating Scale and Simpson--Angus Rating total scores were zero with any changes during the study.

DISCUSSION
==========

To the best of our knowledge, the present study is the first one to investigate the effects of aripiprazole augmentation for treatment of MDDM. The present study aimed to see the potential utility of aripiprazole augmentation for MDDM patients in naturalistic treatment setting and aripiprazole has clearly shown its clinical benefit as augmentation agents in the treatment of MDDM. According to the results, aripiprazole augmentation significantly improved the MADRS total score as well as all other secondary efficacy measures, without any significant AEs during the whole study period. Despite no official treatment guideline has been available for treatment of MDDM, Dr. Stahl group has recently suggested pharmacological treatment guideline proposing atypical antipsychotics including aripiprazole as the first-line treatment for MDDM \[[@b22-cpn-17-495]\].

The MADRS total score change was approximately 7 point which is comparable with those (about 10 points) from other RCTs and open-label studies. In addition, the responder rates by different criteria were approximately 30% to 60%, indicating that proper treatment effects were observed in significant portion of patients. In addition, the remission rate was increased by 15.8% when applying MADRS score cut-off point of 11 as other researchers proposed \[[@b23-cpn-17-495]\].

Another intriguing point is that the reduction of YMRS total score was also quite comparable to that of MADRS and the responder rate by YMRS criteria was approximately two times higher than that by MADRS criteria. This is in line with the previously proven efficacy of aripiprazole for treatment of acute manic or mixed episodes of bipolar I disorder \[[@b24-cpn-17-495],[@b25-cpn-17-495]\].

According to previous subanalyses of aripiprazole MDD RCTs, aripiprazole was proven to be effective regardless of subtype \[[@b12-cpn-17-495]\] or severity \[[@b13-cpn-17-495]\] of MDD, which is in line with our results. Indeed there have been no identified clinical factors (antidepressant type, doses, duration of illness, comorbidity, e.t.c) to be associated with the effects of aripiprazole augmentation in the treatment of MDD yet, which are consistently and similarly observed in subsequent RCTs \[[@b26-cpn-17-495]\] and subanalyes \[[@b27-cpn-17-495],[@b28-cpn-17-495]\].

Meanwhile, aripiprazole dose was low in our study, when reflecting the clinical manifestation of MDDM. This is contrary to what was expected but is supported by other successful clinical experiences of low-dose aripiprazole augmentation for refractory MDD in Asian populations. In addition, our dose (4 mg/day) is in dose range previously reported in MDD RCTs, open trials, and medical data analysis (3 to 12 mg/day) \[[@b26-cpn-17-495],[@b27-cpn-17-495],[@b29-cpn-17-495]--[@b36-cpn-17-495]\]. Indeed, recent Japanese RCT \[[@b26-cpn-17-495]\] has clearly proven equally efficacy between low (3 mg/day) and high dose (10 mg/day) in MDD. In addition, the most recent and largest observation study (n = 1,103) of aripiprazole augmentation for MDD has also reported low dose of 3.5 mg/day used in routine practice. In a recent chart review study (n = 211), low doses of aripiprazole (≤5 mg), has been proposed to be more effective and better tolerated than higher ones in the treatment of bipolar II or bipolar not otherwise specified depression as well \[[@b37-cpn-17-495]\]. A recent bipolar depression RCTs using aripiprazole have failed to show its clear superiority over placebo; one of main reasons was the use of high dose resulting in high rate of early dropout due to EPS and other multiple AEs \[[@b38-cpn-17-495]\]. In addition in the first RCT using atypical antipsychotics (lurasidone) for MDDM \[[@b39-cpn-17-495]\], the dose of lurasidone (36.2 mg/day) was almost half dose of the used in bipolar depression (64.6 mg/day) RCT of lurasidone \[[@b40-cpn-17-495]\]. Finally, the effects of the partial agonist effects of aripiprazole on presynaptic dopamine synthesis in relation to dopamine D2 receptor occupancy was investigated in a recent PET study; occupancy of dopamine D2 receptors corresponded to the doses of aripiprazole, but the changes in dopamine synthesis capacity were not significant, nor was the relation between dopamine D2 receptor occupancy and these changes \[[@b41-cpn-17-495]\]. It is well-known that only 2 mg of aripiprazole would occupy approximately 70% of D2 receptors \[[@b42-cpn-17-495],[@b43-cpn-17-495]\]. Therefore, our results may suggest that aripiprazole dose should not exceed doses usually needed in MDD treatment in routine practice. Moreover, we have to also consider that higher prevalence of CYP2D6\*10 allele, which decreases CYP2D6 enzyme activity, in Asians than in Western population \[[@b26-cpn-17-495],[@b44-cpn-17-495]\].

Our study has clear shortcomings for generalization of the findings. The study design was retrospective with blinding method and placebo. Natural course of the illness or outcome biases could not be excluded. Furthermore, sample size power was proper by statistical calculation but absolute size should not be adequate for clinical translation. Antidepressants were not controlled. Assessment and treatment outcome biases by retrospective design should be also considered. Moreover, recall bias for diagnosis of MDDM should also be considered. Finally, the 2-month study duration was not adequate for proper evaluation of MDDM patients.

In conclusion, our results have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, RCTs for generalizability near future.
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![Changes of outcome measures from baseline in the study. Data represent mean numbers from baseline at each psychometric scale.\
CGI-CB, Clinical Global Impression-Clinical Benefit; CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery--Åsberg Depression Rating Scale; YMRS, Young Mania Rating Scale; SDS, Sheehan Disability Scale.\
All *p* values \< 0.001.](cpn-17-495f1){#f1-cpn-17-495}

![Responder and remitter rates (%) at the end of treatment in the study. Data represent percentage of subjects as indicated.\
MADRS, Montgomery--Åsberg Depression Rating Scale; Worsening or no change, no change or increase of MADRS total score; minimal responder, 0% \< decrease of MADRS total score \< 25%; partial responder, 25% ≤ decrease of MADRS total score \< 50%; responder, ≥ 50% decrease of MADRS total score; remitter, 11 ≤ MADRS total score at the end of treatment.](cpn-17-495f2){#f2-cpn-17-495}

![Improvement rate by Clinical Global Impression-Improvement (CGI-I) score at the end of treatment.\
YMRS, Young Mania Rating Scale; CGI-I responder, subject on score 1 or 2 of CGI-I score at the end of treatment; YMRS responder, ≥ 50% decrease of YMRS total score at the end of treatment.\
Aripiprazole doses: 4.3 ± 3.1 mg/day and 3.9 ± 2.5 mg/day at CGI-I responders and YMRS responders, respectively.](cpn-17-495f3){#f3-cpn-17-495}

![Comparison of distribution of Clinical Global Impression-Clinical Benefit (CGI-CB) scores (1 to 10) between baseline and end of treatment. CGI-CB score of 1 indicates the greatest benefit (effectiveness) with least burden (adverse events) from treatment, whereas score of 10 indicates the least benefit with the greatest burden from the treatment.](cpn-17-495f4){#f4-cpn-17-495}

###### 

Summary of baseline characteristics of the subjects (n = 38)

  Parameter                                     Data
  --------------------------------------------- -------------
  Age (yr)                                      28.4 ± 11.3
  Sex, male                                     25 (65.8)
  Duration of illness (yr)                      4.4 ± 2.9
  Number of MDD episode                         1.9 ± 0.8
  Duration of current MDD episode (mo)          8.5 ± 7.6
  Number of admission                           0.1 (0.2)
  Presence of comorbid medical illness          13 (34.2)
  Presence of past history of admission         10 (26.3)
  Presence of family history                    5 (13.2)
  Socioeconomic status                          
   Middle                                       27 (71.1)
   Low                                          10 (26.3)
  Secured by government                         1 (2.6)
  History of substance use (alcohol/nicotine)   5 (13.2)
  Living status, married                        7 (18.4)
  Education                                     
   ≤ Middle school                              4 (10.5)
   ≥ High school                                34 (89.5)
  Type of antidepressants                       
   SSRIs                                        
    Escitalopram                                18 (47.4)
    Fluoxetine                                  9 (23.7)
    Sertraline                                  3 (7.9)
   SNRIs                                        
    Duloxetine                                  2 (5.2)
    Venlafaxine                                 5 (13.2)
   DNRI                                         
    Bupropion                                   1 (2.6)
  Concomitant anti-anxiety drugs                
   Presence                                     25 (65.8)
    Alprazolam                                  5 (20.0)
    Lorazepam                                   8 (32.0)
    Buspiron                                    5 (20.0)
    Etizolam                                    4 (16.0)
    Others                                      3 (12.0)
   None                                         13 (34.2)
  Psychometirc assessment                       
   CGI-CB                                       8.0 ± 2.4
   CGI-S                                        4.1 ± 2.6
   MADRS                                        21.9 ± 5.4
   YMRS                                         8.9 ± 4.6
   SDS                                          17.4 ± 5.2

Values are presented as mean ± standard deviation or number (%). MDD, major depressive disorder; CGI-CB, Clinical Global Impression-Clinical Benefit; CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery--Åsberg Depression Rating Scale; YMRS, Young Mania Rating Scale; SDS, Sheehan Disability Scale; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; DNRI, dopamine-norepinephrine reuptake inhibitor.
